IndustryCompany release

Corcept Q3 revenue rises 64% to $340.5m as Lifyorli launch contributes $91.4m

🇺🇸 Corcept Therapeutics Inc (CORT) · Tue 03 Nov 2026

Corcept Therapeutics reports third-quarter net income of $126.8m and flags a CHMP positive opinion for relacorilant in ovarian cancer and a December US decision date in Cushing's syndrome.

Corcept Therapeutics reported third-quarter 2026 results on 3 November, with revenue of $340.5m, up 64%. The headline figure includes $91.4m from Lifyorli (relacorilant), which is marketed for platinum-resistant ovarian cancer. Net income for the quarter was $126.8m.

The company reiterated its full-year 2026 revenue guidance of $1.1bn to $1.2bn.

On the regulatory front, Corcept noted that the CHMP adopted a positive opinion in September 2026 on relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer. The company expects European Commission approval by the end of the year.

Corcept also cited a PDUFA goal date of 17 December 2026 for its resubmitted new drug application for relacorilant in Cushing's syndrome. It additionally reported results from Part A of the Phase 2 BELLA study. The summary on file gives no further detail on those findings, and the full source text was not available for this report.

What it means for your team

  • A CHMP positive opinion is not itself a marketing authorisation; the European Commission decision, which Corcept expects by year-end, is the step that confers EU approval.
  • The 17 December 2026 PDUFA date for relacorilant in Cushing's syndrome is the next US regulatory milestone to watch.
  • Market-access teams in oncology may want to track how the Lifyorli launch uptake, at $91.4m in its quarter, develops ahead of any EU rollout.

Company's press release (SEC filing): Corcept Therapeutics Inc ↗

Article written by VigiEye from the official source (Corcept Therapeutics Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →